Roche Invests $850 Million in Regor’s Next-Generation CDK Inhibitors for Breast Cancer Treatment

Acquisition Agreement:
Genentech, a member of the Roche Group, has entered into a definitive purchase agreement to acquire Regor Pharmaceuticals' portfolio of next-generation CDK inhibitors for the treatment of breast cancer.

Financial Terms:
The deal includes an upfront payment of $850 million in cash, with additional cash payments contingent on achieving future development, regulatory, and commercial milestones.

Clinical Development:
Genentech will be responsible for clinical development, manufacturing, and commercialization of the CDK inhibitors worldwide. Regor will continue to manage the two ongoing Phase 1 trials to their completion.

Closing Conditions:
The proposed transaction is expected to close in the fourth quarter of 2024, subject to the satisfaction of customary closing conditions.

Strategic Focus:
This acquisition aligns with Roche's strategy to prioritize the development of transformative medicines, particularly in the area of breast cancer.